



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 18<sup>TH</sup> JULY 2018 AT  
12.30pm

IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,  
ROYAL BLACKBURN HOSPITAL

### PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T MacKenzie (TM)	GP, EL CCG

### In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

### 2018/110: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr Y Naheed (YN)	GP, EL CCG

### 2018/111: DECLARATION OF INTEREST

None declared – relevant to agenda items.

### 2018/112: MINUTES OF JUNE MEETING:

Accepted as a correct record.

### 2018/113: MATTERS ARISING:

**2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines –**  
Awaiting updated guideline to incorporate LCFT elements into local guideline, VG will follow up with specialist.

**2018/073: Rifaxamin – Guidelines for Prescribing** – Document updated and sent to AG for comments from gastroenterology. Two issues require clarification:

- Definition/threshold of 'recurrent' eg. one or more episodes.
- Length of treatment course.

Comments needed back to CCG asap and final document for Sept ELMMB.

**ACTION: Comments to CCG and final document to Sept ELMMB meeting.**

**2018/085: LMMG Recommendations (from Apr LMMG) – DMARDs Shared Care Agreement Form** – VG working with rheumatology pharmacist and clinicians in the first instance with respect to implementation. LMMG are setting up Task & Finish (T&F) group, VG and rheumatology pharmacist to represent ELHT. Bring back to ELMMB when T&F group reports.

### **2018/114: UNLICENSED PRODUCT REQUEST – SODIUM METABISULPHITE 25% IN UNGUENTUM CREAM**

Requested by Dermatology for treatment of extensive calcinosis cutis for patient with no other acceptable alternative treatment. There is some limited evidence for use. It was agreed for one patient, not for formulary inclusion

**Resolved: Sodium Metabisulphite 25% in unguentum cream agreed for one patient on dermatology advice.**

### **2018/115: LMMG CONSULTATIONS (for Sept LMMG)**

None received

### **2018/116: LMMG RECOMMENDATIONS (from June LMMG)**

**Rivaroxaban Extended prevention Recommendation** – accepted as written for use in ELHE. The table on page 3 with explanation of dose to be included on formulary. Appropriate information on dose choice should be included in advice and letters when prescribing rivaroxaban.

**Paravit-CF®** - multivitamin preparation for cystic fibrosis patients containing all relevant vitamins. LR/JV to compare constituents & costs with other preparations to ensure most cost effective. Recommendation accepted as written for use in ELHE pending costings.

### **2018/117: FORMULARY UPDATES**

**Betnesol N® ear drops** – more cost effective than other choices. Add to formulary replacing Gentisone HC ear drops. **Traffic light: Green**

**Tadalafil once daily** – increasing requests for tadalafil once daily from psychosexual services. LR/JV to review ED guideline and formulary and bring back.

**Memantine orodispersible tablets** – to be included as a 3<sup>rd</sup> line option, only if swallowing difficulties. **Traffic light: Amber**

**Estriol cream 0.01% (Gynest)** – to be removed from formulary. Estriol 0.1% (Ovestin) (on formulary) is a more cost-effective alternative.

**Omega 3 Fatty acids** – remove from formulary in accordance with prescribing for clinical need policy. **Traffic light: Black**

**Vitamin K preparations** – now only available as unlicensed preparations. Phytomenadione 10mg tablets to be included on formulary as most cost effective option. **Traffic light: Red**

**Methylphenidate prolonged release (Xaggatin XL®)** – to be included on formulary as cost effective equivalent to Concerta®. **Traffic light: Amber Shared Care**

**Sodium Chloride Nasal drops** - remove from formulary in accordance with prescribing for clinical need policy.

**Ketamine oral** – use in chronic pain has limited clinical evidence and concerns raised over clinical risk and safety. **Traffic light: Black**  
Use by hospice – Traffic light: Red

If a clinician wishes to use ketamine oral for chronic pain a request must be made either through the New Medicines Request Form or IFR process depending on the case.

**Ketamine infusion** – non formulary. **Traffic light: Black**

**Resolved: Formulary to be updated as above**

## **2018/118: ELHT: T34 AMBULATORY SYRINGE PUMP POLICY - UPDATE**

Updated policy acknowledged. To be uploaded to website.

**Resolved: Updated T34 Ambulatory Syringe Pump Policy acknowledged.**

## **2018/119: ELHT: THE PERI PROCEDURAL MANAGEMENT OF PATIENTS ON ANTICOAGULANTS, ANTIPLATELETS & LOW MOLECULAR WEIGHT HEPARIN - UPDATE**

Updated policy approved.

**Resolved: The update to 'The peri procedural management of patients on anticoagulants, antiplatelets & low molecular weight heparin' approved.**

## **2018/120: ELHT: ORAL ANTICOAGULATION GUIDELINES - UPDATE**

Updated policy approved. Recommend add ticagrelor and prasugrel to antiplatelet list on form in Appendix 3.

**Resolved: The update to Oral anticoagulation guidelines, approved.**

## **2018/121: PROTON PUMP INHIBITORS PIL**

EL CCGs are national outliers with respect to volumes of PPIs prescribed. A qualitative clinical audit will be undertaken to review specific cohorts of patients taking PPIs to step down dose or withdraw in line with national guidelines. Dr Collum has been invited to provide an update on GORD. The patient information leaflet will provide patients with supporting information and self-management. Patient information leaflet acknowledged.  
**Resolved: The PPI patient information leaflet acknowledged.**

## **2018/122: ELHE: CARE HOME AUDIT RESOURCES**

Care home Audit documents to be added as a resource for care homes on website.  
**Resolved: Care Home Audit Documents to be added to website.**

## **2018/123: NICE RECOMMENDATIONS (from June)**

Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA522] is recommended as an option by NICE. Approved in line with NICE.

NHS England Cancer Drug Fund

**Traffic Light: RED**

Midostaurin for untreated acute myeloid leukaemia [TA523] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma [TA524] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Arsenic trioxide for treating acute promyelocytic leukaemia [TA526] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Beta interferons and glatiramer acetate for treating multiple sclerosis [TA527] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease [TA217 update] – updated in line with NICE guideline on dementia.

## **STANDING ITEMS**

### **2018/124: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – June 2018**

Minutes acknowledged

### **2018/109: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – June 2018**

Minutes acknowledged

No meeting in August.

**DATE OF NEXT MEETING – Wednesday 19<sup>th</sup> September 2018 12.30pm**, Seminar Room 2, Learning & Development Centre, RBH.

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 18<sup>TH</sup> JULY 2018**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2018/052</b>	<b>LMMG Recommendations (from Feb LMMG) Melatonin guidelines</b> – ELHT guideline to include beneficial response information from LCFT guidance.	Dr Perera	May 18
<b>2018/073</b>	<b>Rifaxamin – Guidelines for Prescribing</b> –Updated document to be sent to gastroenterology with questions for comments. Comment back to CCG. Final document for ELMMB	AG LR/JV	Jul 18 Sept 18
<b>2018/116</b>	<b>LMMG Recommendations (from June LMMG)</b> – Paravit-CF® - compare constituents & costs of similar preparations	LR/JV	Sept 18